Source comparison
Concussion Recovery Peptides 2026 Update: Evidence Comparison
Cerebrolysin BDNF upregulation via TrkB receptor activation IV administration (peptides <10 kDa cross BBB within 45 min) 30–50 mL IV daily × 10–21 days Phase 3 trials in TBI; 14 RCTs published Most evidence-supported for acute TBI; requires IV access; modest e
This comparison does not assign a generated winner or score.
- Cerebrolysin
- BDNF upregulation via TrkB receptor activation
- IV administration (peptides <10 kDa cross BBB within 45 min)
- 30–50 mL IV daily × 10–21 days
- Phase 3 trials in TBI; 14 RCTs published
- Most evidence-supported for acute TBI; requires IV access; modest effect size (1.2-point GOS improvement)
- P21 (CNTF derivative)
- Hippocampal neurogenesis via dentate gyrus stem cell activation
- Subcutaneous injection (lipophilic structure allows CNS entry)
- 1–2 mg SC daily × 14–21 days
- Animal models only; case reports in humans
- Promising for memory/cognitive symptoms; no controlled human trials; good safety profile in rodent models
- Dihexa
- HGF receptor activation → c-Met signaling → synaptogenesis
- Oral or subcutaneous (crosses BBB efficiently)
- 0.5–2 mg SC 2–3× weekly × 4–6 weeks
- Phase 1 safety trial completed (Alzheimer's)
- Extreme potency (7M× BDNF); narrow therapeutic window; seizure risk above 5 mg; reserve for refractory cases